264 related articles for article (PubMed ID: 1643692)
21. New strategies to deliver anticancer drugs to brain tumors.
Laquintana V; Trapani A; Denora N; Wang F; Gallo JM; Trapani G
Expert Opin Drug Deliv; 2009 Oct; 6(10):1017-32. PubMed ID: 19732031
[TBL] [Abstract][Full Text] [Related]
22. Noninvasive nanoparticle strategies for brain tumor targeting.
Sun C; Ding Y; Zhou L; Shi D; Sun L; Webster TJ; Shen Y
Nanomedicine; 2017 Nov; 13(8):2605-2621. PubMed ID: 28756093
[TBL] [Abstract][Full Text] [Related]
23. [Pharmacologic bases of chemotherapy of brain tumors in children].
Vassal G
Bull Cancer; 1990; 77(7):699-713. PubMed ID: 2207360
[TBL] [Abstract][Full Text] [Related]
24. Deriving therapies for children with primary CNS tumors using pharmacokinetic modeling and simulation of cerebral microdialysis data.
Jacus MO; Throm SL; Turner DC; Patel YT; Freeman BB; Morfouace M; Boulos N; Stewart CF
Eur J Pharm Sci; 2014 Jun; 57():41-7. PubMed ID: 24269626
[TBL] [Abstract][Full Text] [Related]
25. Blood-brain barrier and chemotherapeutic treatment of brain tumors.
de Vries NA; Beijnen JH; Boogerd W; van Tellingen O
Expert Rev Neurother; 2006 Aug; 6(8):1199-209. PubMed ID: 16893347
[TBL] [Abstract][Full Text] [Related]
26. AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases.
Yang Z; Guo Q; Wang Y; Chen K; Zhang L; Cheng Z; Xu Y; Yin X; Bai Y; Rabbie S; Kim DW; Ahn MJ; Yang JC; Zhang X
Sci Transl Med; 2016 Dec; 8(368):368ra172. PubMed ID: 27928026
[TBL] [Abstract][Full Text] [Related]
27. Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxel.
Sémiond D; Sidhu SS; Bissery MC; Vrignaud P
Cancer Chemother Pharmacol; 2013 Sep; 72(3):515-28. PubMed ID: 23820961
[TBL] [Abstract][Full Text] [Related]
28. Selective uptake of the somatostatin analog RC-160 across the blood-brain tumor barrier of mice with KHT sarcomas.
Banks WA; Kastin AJ; Radulovic S; Conley FK; Johnson DL; Schally AV
Anticancer Drugs; 1992 Oct; 3(5):519-23. PubMed ID: 1360272
[TBL] [Abstract][Full Text] [Related]
29. [Kinetic analysis of the disposition of hydrophilic drugs in the central nervous system (CNS): prediction of the CNS disposition from the transport properties in the blood-brain and blood-cerebrospinal fluid barriers].
Suzuki H; Sugiyama Y
Yakugaku Zasshi; 1994 Dec; 114(12):950-71. PubMed ID: 7869236
[TBL] [Abstract][Full Text] [Related]
30. Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours?
Kemper EM; Boogerd W; Thuis I; Beijnen JH; van Tellingen O
Cancer Treat Rev; 2004 Aug; 30(5):415-23. PubMed ID: 15245774
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of afatinib, an irreversible ErbB family blocker, in the treatment of intracerebral metastases of non-small cell lung cancer in mice.
Zhang SR; Zhu LC; Jiang YP; Zhang J; Xu RJ; Xu YS; Xia B; Ma SL
Acta Pharmacol Sin; 2017 Feb; 38(2):233-240. PubMed ID: 27840411
[TBL] [Abstract][Full Text] [Related]
32. Blood-brain barrier and treatment of central nervous system tumors.
Wiranowska M
J Fla Med Assoc; 1992 Oct; 79(10):707-10. PubMed ID: 1460453
[TBL] [Abstract][Full Text] [Related]
33. The cluster [Re
Estrada LD; Duran E; Cisterna M; Echeverria C; Zheng Z; Borgna V; Arancibia-Miranda N; Ramírez-Tagle R
Biometals; 2018 Aug; 31(4):517-525. PubMed ID: 29574625
[TBL] [Abstract][Full Text] [Related]
34. Strategies to target drugs to gliomas and CNS metastases of solid tumors.
Milojkovic Kerklaan B; van Tellingen O; Huitema AD; Beijnen JH; Boogerd W; Schellens JH; Brandsma D
J Neurol; 2016 Mar; 263(3):428-40. PubMed ID: 26477024
[TBL] [Abstract][Full Text] [Related]
35. Improving drug delivery to primary and metastatic brain tumors: strategies to overcome the blood-brain barrier.
Parrish KE; Sarkaria JN; Elmquist WF
Clin Pharmacol Ther; 2015 Apr; 97(4):336-46. PubMed ID: 25669487
[TBL] [Abstract][Full Text] [Related]
36. NMS-E973, a novel synthetic inhibitor of Hsp90 with activity against multiple models of drug resistance to targeted agents, including intracranial metastases.
Fogliatto G; Gianellini L; Brasca MG; Casale E; Ballinari D; Ciomei M; Degrassi A; De Ponti A; Germani M; Guanci M; Paolucci M; Polucci P; Russo M; Sola F; Valsasina B; Visco C; Zuccotto F; Donati D; Felder E; Pesenti E; Galvani A; Mantegani S; Isacchi A
Clin Cancer Res; 2013 Jul; 19(13):3520-32. PubMed ID: 23674492
[TBL] [Abstract][Full Text] [Related]
37. Potential Pathways for CNS Drug Delivery Across the Blood-Cerebrospinal Fluid Barrier.
Strazielle N; Ghersi-Egea JF
Curr Pharm Des; 2016; 22(35):5463-5476. PubMed ID: 27464721
[TBL] [Abstract][Full Text] [Related]
38. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means.
Kroll RA; Neuwelt EA
Neurosurgery; 1998 May; 42(5):1083-99; discussion 1099-100. PubMed ID: 9588554
[TBL] [Abstract][Full Text] [Related]
39. Advances in Molecular Imaging of Locally Delivered Targeted Therapeutics for Central Nervous System Tumors.
Tosi U; Marnell CS; Chang R; Cho WC; Ting R; Maachani UB; Souweidane MM
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208698
[TBL] [Abstract][Full Text] [Related]
40. Anticancer agents for treatment of tumors in the central nervous system by correspondent substituent substitution and elucidation by pattern recognition methods.
Bartzatt R
Med Chem; 2012 Mar; 8(2):138-44. PubMed ID: 22385186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
